Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

7P - Global ring study determining reproducibility & comparability of CLDN18 testing assays in gastric cancer


06 Mar 2023


Cocktail & Poster Display session


Bharat Jasani


Annals of Oncology (2023) 8 (1suppl_2): 100899-100899. 10.1016/esmoop/esmoop100899


B. Jasani1, H. Schildhaus2, A. Dodson3, S. Parry3, S. Clare-Antony1, N. Atkey1, P. Taniere4

Author affiliations

  • 1 Diaceutics, Diaceutics PLC, BT96GW - Belfast/GB
  • 2 Pathology/medical Affairs, Discovery Life Sciences Biomarker Services GmbH, 34119 - Kassel/DE
  • 3 Director, UK NEQAS for Immunocytochemistry and In-Situ Hybridisation, EC1R5HL - London/GB
  • 4 Cellular Pathology, Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust, B15 2TH - Birmingham/GB


This content is available to ESMO members and event participants.

Abstract 7P


Claudin-18.2 (CLDN18.2) the dominant isoform of CLDN18 in gastric tissue is a highly specific tight junction protein of the gastric mucosa expressed in gastric cancer & has emerged as a promising drug target. Zolbetuximab, a monoclonal antibody (Ab) targeting CLDN18.2 is reported to improve progression free & overall survival in combination with chemotherapy in the first-line treatment of CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric (G) & gastroesophageal junction (GEJ) cancers in 2 randomized phase 3 studies. Both studies (SPOTLIGHT, GLOW) met their primary endpoints. Patient selection for CLDN18.2 in these studies used the Ventana CLDN18 (43-14A) assay. It is important in the clinical setting to ensure accurate & reproducible results in the diagnosis of G/GEJ cancer for treatment options. This global ring study was conducted to assess analytical reproducibility & concordance of this assay with 2 other CLDN18 Abs (LSBio LS–B16145-100 & Novus Biologicals NBP2-32002) stained on 3 platforms to confirm possible diagnostic testing methods.


Tissue microarray (TMA) of 15 gastric cancer samples in triplicate cores was provided to 27 labs across 11 countries. Each lab stained the TMAs using 2-3 CLDN18 Abs with optimized protocols. The TMAs, also stained by the central lab, were used to achieve consensus by expert review. Using agreed scoring algorithms as per the phase 3 studies, IHC scores were generated per core & the results were collated for statistical analysis with the consensus results.


Show high concordance among the 3 Abs across the assessed parameters when performed on each of the 3 platforms, with the highest accuracy & sensitivity observed for Ventana Ab & LSBio Ab across all 3 platforms. Table: 7P

Precision Precision Precision Accuracy Accuracy Accuracy Sensitivity Sensitivity Sensitivity Specificity Specificity Specificity
Antibody Ventana Novus LSBio Ventana Novus LSBio Ventana Novus LSBio Ventana Novus LSBio
Ventana 0.96 0.88 0.94 0.95 0.88 0.88 0.93 0.67 0.85 0.97 0.96 0.92
Dako - 0.94 0.93 - 0.83 0.94 - 0.72 0.96 - 0.95 0.93
Leica - 0.79 0.97 - 0.94 0.93 - 0.89 0.91 - 0.95 0.96


The study shows multiple Abs applied on multiple platforms give highly reproducible and comparable results for detecting CLDN18.2 in gastric cancer providing a potential for their global adoption for CLDN18 testing.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Diaceutics PLC.


Astellas Pharma.


B. Jasani, A. Dodson, S. Parry, N. Atkey, P. Taniere: Non-Financial Interests, Institutional, Advisory Role, Performing consulting work on behalf of Astellas Pharma in regards to abstract being submitted’: Astellas Pharma. H. Schildhaus: Financial Interests, Institutional, Advisory Board: MSD, BMS, Novartis; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Roche, Takeda, Agilent, ZytoVision; Financial Interests, Personal, Full or part-time Employment: Targos/DLS Inc.; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Funding: Blueprint medicines; Other, Personal, Other, Member of the QuIP Board (Quality Assurance Organisation): QuIP GmbH. S. Clare-Antony: Other, Institutional, Advisory Role, Performing consulting work on behalf of Astellas Pharma in regards to abstract being submitted: Astellas Pharma.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.